Common Variable Immunodeficiency Associated with a De Novo IKZF1 Variant and a Low Humoral Immune Response to the SARS-CoV-2 Vaccine

Background and Aims: Common variable immunodeficiency (CVID) comprises a group of diseases with heterogeneous clinical and immunological manifestations. Several mutations have been identified in genes encoding proteins essential for immune function. Our aim was to phenotypically and genotypically characterize a patient diagnosed with CVID and study his response to the SARS-CoV-2 vaccine. Methods: We performed a next-generation sequencing analysis, a CMIA, and an ELISA to analyze the humoral and cellular response to the SARS-CoV-2 vaccine, respectively. We also employed flow cytometry and immunoturbidimetry to assess the patient’s global immune status. Results: We found a low humoral but positive cellular response to the SARS-CoV-2 vaccine. NGS screening revealed a transition from guanine to adenine at position c.485 of the IKZF1 gene in heterozygosity, giving rise to the R162Q variant, which was not present in his parents. Conclusions: The R162Q variant of the IKZF1 gene has been associated with CVID type 13, but always with an autosomal dominant inheritance with high penetrance. Therefore, we present for the first time a case of CVID associated with a de novo heterozygous R162Q variant in the IKZF1 gene in a patient with a low humoral immune response to the complete COVID-19 vaccination program.

[1]  H. Ljunggren,et al.  Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency , 2022, Journal of Clinical Immunology.

[2]  D. Montefiori,et al.  Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.

[3]  Scott M Elliott,et al.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.

[4]  O. Cabrera-Marante,et al.  Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency , 2021, Journal of Clinical Immunology.

[5]  P. Palma,et al.  Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies , 2021, Frontiers in Immunology.

[6]  M. Addo,et al.  SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients , 2021, Clinical Gastroenterology and Hepatology.

[7]  S. Pancani,et al.  The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays , 2021, International Immunopharmacology.

[8]  E. Leung,et al.  Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19 , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[9]  B. Grimbacher,et al.  There is no gene for CVID - novel monogenetic causes for primary antibody deficiency. , 2021, Current opinion in immunology.

[10]  C. von Kalle,et al.  Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany , 2021, Emerging infectious diseases.

[11]  N. Freund,et al.  Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.

[12]  S. Rosenzweig,et al.  Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology , 2021, Expert review of clinical immunology.

[13]  S. Rosenzweig,et al.  IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity , 2021, Journal of Clinical Immunology.

[14]  S. Rosenzweig,et al.  IKAROS Family Zinc Finger 1-Associated Diseases in Primary Immunodeficiency Patients. , 2020, Immunology and allergy clinics of North America.

[15]  J. Casanova,et al.  Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee , 2020, Journal of Clinical Immunology.

[16]  A. Rawat,et al.  Recent advances in elucidating the genetics of common variable immunodeficiency , 2019, Genes & diseases.

[17]  S. Ehl,et al.  The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. , 2019, The journal of allergy and clinical immunology. In practice.

[18]  C. Smulski,et al.  Assessing the Functional Relevance of Variants in the IKAROS Family Zinc Finger Protein 1 (IKZF1) in a Cohort of Patients With Primary Immunodeficiency , 2019, Front. Immunol..

[19]  A. Aghamohammadi,et al.  Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical manifestations, Diagnosis, Classification and Management. , 2020, Journal of investigational allergology & clinical immunology.

[20]  Susan M. Schlenner,et al.  A kindred with mutant IKAROS and autoimmunity. , 2018, The Journal of allergy and clinical immunology.

[21]  A. Fischer,et al.  Dominant‐negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency , 2018, The Journal of clinical investigation.

[22]  B. Scheijen,et al.  The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia , 2018, Haematologica.

[23]  C. Bonroy,et al.  A novel IKAROS haploinsufficiency kindred with unexpectedly late and variable B-cell maturation defects , 2017, The Journal of allergy and clinical immunology.

[24]  Yang Wang,et al.  B-cell Deficiency: A De Novo IKZF1 Patient and Review of the Literature. , 2018, Journal of investigational allergology & clinical immunology.

[25]  S. Miyano,et al.  Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations , 2017, The Journal of allergy and clinical immunology.

[26]  H. Volk,et al.  Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. , 2016, Vaccine.

[27]  S. South,et al.  Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. , 2016, The New England journal of medicine.

[28]  C. Cunningham-Rundles,et al.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. , 2016, The journal of allergy and clinical immunology. In practice.

[29]  Chunhua Song,et al.  Congenital pancytopenia and absence of B lymphocytes in a neonate with a mutation in the ikaros gene , 2012, Pediatric blood & cancer.

[30]  C. Kallenberg,et al.  Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency. , 2011, Clinical immunology.